ストックスクリーナーアプリを入手
1.965
7.82%
-0.145
Immix Biopharma Inc (IMMX) 最新ニュース
Immix Biopharma’s NXC-201 Achieves 70% Complete Response Rate in AL Amyloidosis Trial - Insider Monkey
H.C. Wainwright reaffirms Immix Biopharma stock Buy rating after trial By Investing.com - Investing.com India
immix biopharma enters at-the-market offering agreement By Investing.com - Investing.com South Africa
Immix Biopharma's NXC-201 Trial Meets Primary Endpoint in AL Amyloidosis - marketscreener.com
Immix Biopharma stock soars to 52-week high of $2.99 - Investing.com Australia
Immix Biopharma Enters At The Market Offering Agreement - TipRanks
immix biopharma enters at-the-market offering agreement - Investing.com
Immix Biopharma reports high response rate in AL Amyloidosis trial By Investing.com - Investing.com India
Immix Biopharma stock soars to 52-week high of $2.99 By Investing.com - Investing.com India
Immix Biopharma Reports 70% Complete Response Rate for NXC-201 in Phase 1/2 AL Amyloidosis Trial at ASCO 2025 - Nasdaq
Immix Biopharma Announces Primary Endpoint Met in positive - GlobeNewswire
Immix Biopharma Announces Primary Endpoint Met in positive NXC-201 Interim Results Presented at ... - Eagle-Tribune
Immix Biopharma — Positive newsflow continues for NEXICART-2 - Smartkarma
Immix Biopharma accelerates NEXICART-2 trial enrollment By Investing.com - Investing.com South Africa
Immix Biopharma Further Expands U.S. Clinical Sites for Relapsed/Refractory AL Amyloidosis Trial Nexicart-2 - marketscreener.com
Immix Biopharma (IMMX) Expands NEXICART-2 Trial Sites | IMMX Sto - GuruFocus
Immix Biopharma (IMMX) Expands NEXICART-2 Trial Sites | IMMX Stock News - GuruFocus
Immix Biopharma accelerates NEXICART-2 trial enrollment - Investing.com
Immix Biopharma Further Expands U.S. Clinical Sites for relapsed/refractory AL Amyloidosis Trial NEXICART-2 - marketscreener.com
Immix Amyloidosis Trial Surges: 10 New Sites Added, ASCO Data Presentation Coming - Stock Titan
Immix Biopharma (NASDAQ:IMMX) Trading Up 15.3% – Should You Buy? - Defense World
Immix Biopharma reports promising trial results for NXC-201 By Investing.com - Investing.com India
Immix Biopharma reports promising trial results for NXC-201 - Investing.com Australia
Immix Biopharma Reports Positive ASCO Abstract Results for NXC-201 from NEXICART-2 Trial in Relapsed/Refractory AL Amyloidosis - Nasdaq
Immix Biopharma Announces Positive Results for NXC-201 at - GlobeNewswire
Immix Biopharma Announces Positive Results for NXC-201 at ASCO Oral Presentation, Enabling Pathway to Best-in-Class Therapy for relapsed/refractory AL Amyloidosis - Yahoo Finance
Immix Biopharma Announces Positive Results for NXC-201 at ASCO Oral Presentation, Enabling ... - Eagle-Tribune
Immix Biopharma to Host KOL Event to Discuss NXC-201 - GlobeNewswire
We're Keeping An Eye On Immix Biopharma's (NASDAQ:IMMX) Cash Burn Rate - Yahoo Finance
Immix Biopharma — Steady progress in Q125 - Smartkarma
Immix Biopharma Inc expected to post a loss of 23 cents a shareEarnings Preview - TradingView
Immix Biopharma (IMMX) to Release Earnings on Thursday - Defense World
Favourable Signals For Immix Biopharma: Numerous Insiders Acquired Stock - simplywall.st
Immix Biopharma Announces Oral Presentation of NXC-201 Phase 1/2 Trial Data at ASCO 2025 - Nasdaq
Immix Biopharma’s NXC-201 NEXICART-2 Clinical Trial Data Selected for Oral Presentation at ASCO 2025 - GlobeNewswire
Groundbreaking CAR-T Therapy for AL Amyloidosis: First US Trial Data Earns Prestigious ASCO Spotlight - Stock Titan
Immix Biopharma — All eyes on NEXICART-2 - Smartkarma
Immix Biopharma (IMMX) Expected to Announce Earnings on Friday - Defense World
Immix Biopharma Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Immix Biopharma Inc. (IMMX) reports earnings - Quartz
Immix Biopharma (IMMX) Projected to Post Quarterly Earnings on Thursday - Defense World
Immix Biopharma — NXC-201 receives FDA RMAT designation - Smartkarma
SBI Securities Co. Ltd. Purchases New Stake in Immix Biopharma, Inc. (NASDAQ:IMMX) - Defense World
Immix Biopharma (NASDAQ:IMMX) Trading Down 9% – Here’s Why - Defense World
HC Wainwright Reaffirms Buy Rating for Immix Biopharma (NASDAQ:IMMX) - MarketBeat
FDA Awards RMAT Designation to NXC-201 for Relapsed/Refractory AL Amyloidosis - OncLive
Immix Biopharma stock holds $7 target, Buy rating at H.C. Wainwright - MSN
Immix Biopharma stock holds $7 target, Buy rating at H.C. Wainwright By Investing.com - Investing.com South Africa
Immix Biopharma’s (IMMX) “Buy” Rating Reaffirmed at HC Wainwright - Defense World
Immix Biopharma’s CAR-T NXC-201 Snags FDA RMAT Designation for Light Chain Amyloidosis - CGTLive™
Buy Rating for Immix Biopharma: Promising Clinical Advancements and Market Potential of NXC-201 - TipRanks
Immix Biopharma Says FDA Grants Regenerative Medicine Advanced Therapy Designation to NXC-201 Cell Therapy - Marketscreener.com
Immix Biopharma Receives FDA RMAT Designation For NXC-201 -February 10, 2025 at 10:15 am EST - Marketscreener.com
Think Lucid Group is Expensive? This Chart Might Change Your Mind. - The Globe and Mail
Immix Biopharma Receives FDA Regenerative Medicine Advanced - GlobeNewswire
Breakthrough: IMMX Secures Elite FDA Status for First-Ever AL Amyloidosis CAR-T Treatment - StockTitan
0.87%
0.19%
大文字化:
|
ボリューム (24 時間):